Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

BioRationality: A Calculated View on the Future of Biosimilars

August 21st 2023

By Sarfaraz K. Niazi, PhD

Article

Sarfaraz K. Niazi, PhD, recapped his answers to a recent interview where he discussed his predictions on the future of the biosimilar industry in the United States.

How Streamlining Development Can Save the US Biosimilar Industry

August 20th 2023

By Skylar Jeremias

Podcast

On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, expanded on ways to make biosimilar development faster and cheaper without compromising on safety and efficacy and how these practices can ensure a sustainable market for the future.

The Top 5 Biosimilar Articles for the Week of August 14

August 18th 2023

By Skylar Jeremias

Video

Here are the top 5 biosimilar articles for the week of August 14, 2023.

Biocon Biosimilar Quarterly Sales Up 106%

August 17th 2023

By Skylar Jeremias

Article

In Biocon’s latest quarterly earnings report, the company revealed that sales for its biosimilars portfolio rose 106% compared with the same time frame the year prior.

STADA Earnings Project Record Breaking Profits for 2023

August 16th 2023

By Skylar Jeremias

Article

In STADA Arzneimittel’s first half of 2023 earnings report, the company disclosed double-digit growth, suggesting that it could see profits hit an all-time high by the end of the year.

Future Opportunities With Interchangeable Biosimilars

August 15th 2023

Video

A panel of experts discuss future opportunities with interchangeable biosimilars from payer and provider perspectives.

Addressing the Increased Amount of Interchangeable Biosimilars in the Market

August 15th 2023

Video

Experts review best practices around plan design that payers and plan sponsors should address as more interchangeable biosimilars potentially enter the market.

Interchangeable Biosimilar Automatic Substitution

August 15th 2023

Video

Jonathan Kay, MD, and Kimberly C. Chen, DO, MSHLM, discuss clinical and financial concerns related to automatic substitution at the pharmacy for an interchangeable biosimilar from a payer perspective.

Study: Ranibizumab Biosimilar Is the Most Cost-Effective Option for nAMD

August 15th 2023

By Justina Petrullo

Article

Ranibizumab biosimilar was found to be the most cost-effective for neovascular age-related macular degeneration (nAMD), according to a recent Japanese study.

Contributor: The Promise of RA Biosimilars Could Be Realized, but Greater Adoption Rates Are Needed

August 14th 2023

By Robert Zutaut, RPh

Article

Robert Zutaut, RPh, a clinical specialist from McKesson Provider Solutions, quantifies the major barriers to adoption for biosimilars used to treat rheumatoid arthritis (RA) and some major considerations for health systems looking to address them.